Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.79 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.79 |
| ▸ | AR | P10275 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | ESRRB | O95718 | 3/20 | 0.47 |
| ▸ | ESRRA | P11474 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16586109 | 0.98 | ESR1 (0.77) | ESR1ESR2ARMEN1KMT2A | |
| SCHEMBL3007819 | 0.87 | ESR1 (0.71) | ESR1ESR2ARCYP1A2RAB9A | |
| SCHEMBL396736 | 0.87 | AR (0.65) | ESR1ESR2ARMEN1KMT2A | |
| SCHEMBL28992074 | 0.84 | ESR1 (0.77) | ESR1ESR2ARMAOAMAOB | |
| SCHEMBL25722370 | 0.82 | ESR1 (0.80) | ESR1ESR2ARMEN1KMT2A | |
| SCHEMBL17689179 | 0.82 | ESR1 (0.80) | ESR1ESR2ARMEN1KMT2A | |
| SCHEMBL28992118 | 0.82 | ESR1 (0.80) | ESR1ESR2ARMEN1KMT2A | |
| SCHEMBL16829469 | 0.82 | ESR1 (0.63) | ESR1ESR2ARKMT2ACYP1A2 | |
| SCHEMBL1289517 | 0.82 | ESR1 (0.73) | ESR1ESR2ARESRRBESRRA | |
| SCHEMBL17306551 | 0.81 | BACE1 (0.65) | ESR1ESR2ARMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4545079-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | Toray Industries, Inc. (JP) | 2025-04-30 | — | — | EP | disclosed |
| CN-119403554-A | Therapeutic or prophylactic agent for amyotrophic lateral sclerosis | 东丽株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2024-04-11 | — | — | US | disclosed |
| WO-2023249106-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249107-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249105-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648245-A | Tetrahydroquinoline derivative and medical application thereof | 东丽株式会社 | 2023-08-25 | — | — | CN | disclosed |
| CN-109988106-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022138888-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | 東レ株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | AIFM2, TXNRD2, NFE2L2 | ESR1 3731/4885ESR2 1215/4885AR 3406/4885 |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | AIFM2, GPX1, SOD1 | ESR1 3396/4885ESR2 860/4885AR 3288/4885 |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | AIFM2, GPX1, GPX4 | ESR1 3178/4885ESR2 411/4885AR 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.